Biomedical engineer Leyla Soleymani’s team was responsible for the hardware, including the chip that reads the sample.
Researchers at McMaster and Brock universities have created the prototype for a hand-held device to measure a biomarker for cancer, paving the way for home-based cancer monitoring and to improve access to diagnostic testing.
The device works much like the monitors that people with diabetes use to test their blood-sugar levels and could be used in a medical clinic or at home, all without lab work, greatly simplifying the process for testing blood for cancer’s signature.
A user would mix a droplet of blood in a vial of reactive liquid, then place the mixture onto a strip and insert it into a reader. In minutes, the device would measure an antigen that indicates the degree to which cancer is present.
The prototype has been designed to monitor prostate specific antigen (PSA) and the technology can readily be adapted to measure other markers, depending on the form of cancer or other chronic disease.
The ability to collect such information at home would make the daily lives of patients much easier while also generating accurate, shareable, up-to-the-minute results to guide their doctors in shaping care and treatment – all at a lower cost to the health-care system.
The device would also allow patients to continue to monitor their health after treatment.
The prototype was created by a research collaboration led by McMaster’s Leyla Soleymani, a biomedical engineer and Canada Research Chair in Miniaturized Biomedical Devices, and Brock’s Feng Li, an associate professor of chemistry who leads a bioanalytical chemistry lab.
Soleymani’s team (also including Sarah Traynor and Richa Pandey) was responsible for the hardware, including the chip that reads the sample, while Li’s team (also including Guan Wang) created the technology that analyzes the sample.
“This is another step toward truly personalized medicine,” Soleymani says. “We’re getting away from centralized, lab-based equipment for this kind of testing.
“This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples.”
Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis, Li says.
“Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives.”
The researchers’ proof-of-concept work is described in an article published in the journal Angewandte Chemie. The invention will need to be tested more broadly before earning the regulatory approvals that would permit commercial manufacturing
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cancer biomarkers
- Cyclin D1 expression may be a biomarker for penile cancer
A new research paper titled "Cyclin D1 expression in penile cancer" has been published in Oncotarget. In this new study, researchers analyzed the expression profile of cyclin D1 in patients with ...
- New PET imaging biomarker Gal-1 predicts tumor responses to immunotherapy
The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning ...
- Liquid Biopsy Market to Grow at 13.1% CAGR, Revolutionizing Cancer Diagnostics
The global liquid biopsy market is projected to grow significantly, with an estimated value of USD 35.3 billion by 2033, up from USD 10.3 billion in 2023, reflecting a compound annual growth rate ...
- Using open research tools to uncover a new therapeutic target for an aggressive blood cancer
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...
- Newly identified PET biomarker predicts success of immune checkpoint blockade therapy
The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning ...
Go deeper with Google Headlines on:
Cancer biomarkers
[google_news title=”” keyword=”cancer biomarkers” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cancer biomarker detector
- Liquid Biopsy Market to Grow at 13.1% CAGR, Revolutionizing Cancer Diagnostics
The global liquid biopsy market is projected to grow significantly, with an estimated value of USD 35.3 billion by 2033, up from USD 10.3 billion in 2023, reflecting a compound annual growth rate ...
- Blood test could detect preeclampsia in first trimester, LabCorp reports
Preeclampsia can be a life-threatening complication of pregnancy, but a new blood test can help predict a woman's risk for the condition while she is in her first trimester, the test's maker said ...
- Early Cancer Detection Breakthrough: Blood Proteins Could Signal Cancer Up To Seven Years Earlier
Groundbreaking research has revealed blood proteins that might serve as early indicators of cancer, potentially alerting individuals up to seven years prior to a diagnosis. The study identified 618 ...
- Self-assembled Na-doped zinc oxide for the detection of lung cancer biomarker VOCs at low concentrations
Developing high-performance gas sensors for the detection of lung cancer markers at low concentrations is a crucial step towards achieving early lung cancer monitoring through breath tests. Metal ...
- Intense ultrasound extracts genetic info for less invasive cancer biopsies #ASA186
At the University of Alberta, researchers explored how intense ultrasound can release biological indicators of disease from cells. These biomarkers can help identify different types of cancer and ...
Go deeper with Google Headlines on:
Cancer biomarker detector
[google_news title=”” keyword=”cancer biomarker detector” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]